You just read:

MabVax Therapeutics Reports Interim Safety and Imaging Results from Phase I Clinical Trials in HuMab-5B1 Antibody Development Programs

News provided by

MabVax Therapeutics Holdings, Inc.

Nov 14, 2016, 09:00 ET